Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Tachikawa-shi, Japan Clinical Trials

A listing of Tachikawa-shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (87) clinical trials

A Study of Ibrutinib in Combination With Rituximab in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment nave or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

Phase

0.55 miles

Learn More »

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Two separate registration trials conducted under one protocol number are proposed to adequately and independently evaluate the addition of glasdegib in intensive and non-intensive chemotherapy populations. Each study will have an experimental treatment arm and a placebo arm. Endpoints are the same for each study except where specifically indicated. Assignment …

Phase

0.55 miles

Learn More »

A Study of ASP2215 (Gilteritinib) by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Patients considered an adult according to local regulation at the time of obtaining informed consent may participate in the study. Safety Cohort Prior to initiation of the randomized trial, 8 to 12 patients will be enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the …

Phase

0.55 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess …

Phase

3.12 miles

Learn More »

Pivotal Study to Assess the Efficacy Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Approximately 68 weeks including a 4-week screening period, a 52-week treatment period, and 12 weeks of follow-up.

Phase

3.12 miles

Learn More »

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin Once a Day

The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if …

Phase

3.35 miles

Learn More »

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.

Phase

3.35 miles

Learn More »

Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects 1 Month to <17 Years Undergoing MRI Scans

This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects 1 month to <17 years of age undergoing MRI scans in the US and Japan.

Phase

3.35 miles

Learn More »

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

Phase

3.35 miles

Learn More »